Medical devices don't run on patents alone. Selling in Korea requires MFDS device clearance; expanding to the US, EU, and Japan adds FDA, CE, and PMDA pathways. The catch: regulatory submission data (clinicals, technical files, design dossiers) overlaps with patent novelty/inventive-step evidence — and mismanaged disclosure timing makes your own application destroy its own novelty. This article maps how Korean device companies should run IP and regulatory clearance on a single calendar.
Korean medical-device classes
The Medical Device Act Enforcement Rule classifies medical devices into four risk classes. Each class triggers a different MFDS path and timeline, so confirm your class up front and align the IP calendar to it.
| Class | Risk | Pathway | Examples |
|---|---|---|---|
| Class I | Minimal | Notification only | Surgical scissors, generic bandages |
| Class II | Low | Technical-file review / certification | Blood-pressure monitors, contact lenses |
| Class III | Moderate | Technical-file review + clinical data | Ultrasound diagnostics, vascular grafts |
| Class IV | High | Clinical trial + MFDS approval | Pacemakers, heart valves, implants |
MFDS clearance ↔ patent — the data overlaps
MFDS submissions consist of technical files, electrical safety, biocompatibility, clinical trial results, and usability validation. This is the same data that supports patent inventive-step / effect arguments. Run them in parallel and one set of studies feeds both — significant cost savings if you sequence right.
But disclosure order matters. Patents need novelty, so any public-facing regulatory step — MFDS submission, clinical-trial registry entry, conference paper — that goes out before filing kills your own novelty. Public clinical registries (CRIS, ClinicalTrials.gov) count as public disclosure from the moment of registration. Aim to complete patent filing well before any registry entry or paper submission.
Going to the US — 510(k) vs PMA
FDA 510(k) covers Class I/II devices and requires "substantial equivalence to a predicate device," typically clearing in 90-180 days. Class III high-risk devices need PMA, with clinical data and months to over a year of review.
510(k) submissions push strong similarity to a predicate device for fast clearance — but the same similarity raises the odds of patent infringement against the predicate's owner. The submission itself can become evidence in an infringement case. Standard practice is a freedom-to-operate (FTO) analysis of predicate patents before filing the 510(k).
Medical-device claim drafting — four shapes
- Apparatus: "A medical device comprising element A and element B" — name the mechanical components
- System: "A monitoring system comprising a sensor, a processor, and a display" — best fit for IoT and digital-health devices
- Method (excluding medical acts): "A method of analyzing data to produce …" — Korean law excludes medical procedures themselves; reframe as information-processing on data, not as treatment
- Program / medium (SaMD): "A non-transitory computer-readable medium storing a program that causes a computer to …" — standard for Software as a Medical Device
Patent term extension for regulatory delay
KIPO's patent-term extension scheme extends patent term to compensate for clinical-trial and review periods that delayed market entry — well-known for pharmaceuticals, with limited applicability to medical devices and IVDs. Verify whether your specific device qualifies before filing; it materially affects portfolio economics if it does.
A six-phase commercialization timeline
- Phase 1 (R&D): file a Korean provisional to lock priority on core inventions
- Phase 2 (preclinical): file regular patents — split apparatus and SaMD claim sets
- Phase 3 (6 months pre-clinical): start MFDS GMP / technical-file review and run a US 510(k) FTO analysis
- Phase 4 (clinical registration): confirm every core claim is filed before any registry entry
- Phase 5 (post-clearance): design registration (industrial design), trademark registration (brand), and patent-term extension where applicable
- Phase 6 (post-launch): infringement monitoring + trade-secret control over manufacturing process and tuning parameters
- Korean classes
- 1-4 by potential risk
- FDA 510(k)
- 90-180 days Class I/II
- FDA PMA
- Months to 1+ year Class III
- Patent term extension
- Up to 5 years for delayed regulatory review
- Clinical registry → self-disclosure
- From registration file before then
Frequently asked questions
Are medical procedures themselves patentable in Korea?
No. Methods of diagnosis, treatment, or surgery on the human body are excluded for lack of "industrial applicability." But methods that process samples separated from the body or information-processing performed by the device can be patented when separable from the medical act. Reframe "a method by which a doctor diagnoses" as "a method by which the device analyzes".
How much clinical data should I disclose in the spec?
Enough to support inventive step and the claimed effect — typically subject count, primary endpoints, and statistical significance. Anything in the published spec is public, so split: include disclosable summary results in the spec; keep detailed measurements and tuning parameters as trade secrets.
Korean filing vs FDA 510(k) — which first?
Korean filing first as a rule. FDA 510(k) eventually publishes, and the technical-characteristics statements you make there can narrow your own novelty/inventive-step. Complete Korean and PCT filings before scheduling 510(k) submission for IP safety.
Run medical-device IP + regulatory on one calendar with iphere
Provisionals, regular patents, MFDS, FDA 510(k), designs, trademarks, and patent-term extensions — sequenced to avoid self-disclosure and keep priority intact.